✦ LIBER ✦

Development of Herceptin resistance in breast cancer cells

✍ Scribed by Timothy Kute; Christopher M. Lack; Mark Willingham; Bimjhana Bishwokama; Holly Williams; Kathy Barrett; Tanita Mitchell; James P. Vaughn

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 290 KB
Volume: 57A
Category: Article
ISSN: 0196-4763
DOI: 10.1002/cyto.a.10095

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reversal of doxorubicin resistance in br

Reversal of doxorubicin resistance in breast cancer cells by photochemical internalization

✍ Pei-Jen Lou; Ping-Shan Lai; Ming-Jium Shieh; Alexander J. MacRobert; Kristian Be 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 291 KB

## Abstract Multiple drug resistance (MDR) is a problem that seriously reduces the efficacy of many chemotherapy agents. One mechanism for MDR is increased acidification of endocytic vesicles and increased cytosol pH, so weak base chemotherapeutic agents, including doxorubicin, are trapped in endoc

Developments in chemotherapy of breast c

Developments in chemotherapy of breast cancer

✍ Gabriel N. Hortobagyi 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Interleukin-2 enhances the natural kille

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 / neu-positive breast cancer cells

✍ William E. Carson; Robin Parihar; Matthew J. Lindemann; Nicola Personeni; Julie 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

Overcoming radiation resistance in infla

Overcoming radiation resistance in inflammatory breast cancer

✍ Wendy A. Woodward; Bisrat G. Debeb; Wei Xu; Thomas A. Buchholz 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

Characterization of BCAR4, a novel oncog

Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells

✍ Marcia Godinho; Danielle Meijer; Buddy Setyono-Han; Lambert C.J. Dorssers; Ton v 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB

Resistance to the antiestrogen tamoxifen remains a major problem in the management of estrogen receptor-positive breast cancer. Knowledge on the resistance mechanisms is needed to develop more effective therapies. Breast cancer antiestrogen resistance 4 (BCAR4) was identified in a functional screen

Identification of a novel breast-cancer-

Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells

✍ Lambert C.J. Dorssers; Jos Veldscholte 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 177 KB 👁 2 views

Development of anti-estrogen resistance limits the benefit of endocrine therapy of breast cancer. The mechanistic basis for resistance to the anti-estrogen tamoxifen may involve (epi)genetic alterations within tumor cells. We have initiated a random search for genes allowing estrogen-dependent ZR-75